[Translated in English from a tribune published in the French newspaper L’Opinion on October 27th 2022].
The health crisis has demonstrated with a brutality that has shocked – and sometimes bruised – many of our fellow citizens: Europe, and in particular France, has lost control of the supply chain of its health products, particularly of some of its Medicines of Major Therapeutic Interest (MMTI).
In his introductory speech, His Serene Highness Prince Albert II of Monaco stated: “I am especially pleased that the Principality of Monaco is able to welcome your work, support it and contribute to its success. I also welcome the dialogue that has been established between eureKARE and the Scientific Center of Monaco, in particular the opportunity to host one of your studios on its premises, like those you have already set up in various scientific centers across Europe”.
Organized by eureKARE and the Centre Scientifique de Monaco (CMS), SynBio Day, a conference about synthetic biology, took place in mid-October in the Principality of Monaco, giving an opportunity to discuss advances in technologies with tremendous potential.
Following the success of the inaugural 2021 event, SynBio Day 2022 will bring together researchers, industry partners, government representatives and investors to discuss the opportunities and challenges of applying synthetic biology solutions to tackle climate change and benefit our environment.
eureKARE launches synthetic biology studio network with inaugural biomedical studio in Belgium.
Georges Rawadi appointed eureKARE’s Chief of Biotech Studio Development.
It’s our one-year anniversary and we’re celebrating all the exciting events and milestones that took place.
eureKARE announces the successful IPO on Euronext Paris of eureKING, the first European SPAC1 in healthcare dedicated to biomanufacturing that has been co-founded by eureKARE.
This collaboration aims to complete NovoBiome’s disruptive NovoSift® ex-vivo research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.
DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, today announced the completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.
Luxembourg | France | Belgium
Subscribe to our news to keep in touch
